PDCD1 and hepatocellular carcinoma: Anti-PD-1/PD-L1 therapy (22, 31) have been reported to prevent or re-sensitize acquired resistance of HCC cells to sorafenib, though some request additional concomitant agents, such as CXCR4 inhibitors (20).